Intellia Therapeutics, Inc. (0JBU.L) LSE
13.10
-0.98(-6.96%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.10
-0.98(-6.96%)
Currency In USD
Address
40 Erie Street
Cambridge, MA 02139
United States of America (the)
Phone
857 285 6200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
403
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| John Leonard | President, Chief Executive Officer & Director | 1.26M | 1957 |
| Michael Dube | VP & Chief Accounting Officer | 478,489 | 1978 |
| Birgit Schultes | Executive VP & Chief Scientific Officer | 708,860 | 1963 |
| James E. Basta | Executive Vice President, General Counsel & Corporate Secretary | 732,367 | 1966 |
| David Lebwohl | Executive Vice President & Chief Medical Officer | 781,359 | 1955 |
| Edward J. Dulac | Executive Vice President, Chief Financial Officer and Treasurer | 853,712 | 1976 |
| Jennifer A. Doudna | Founder and Member of Scientific Advisor Board | 1.38M | 1964 |
| Rodolphe Barrangou | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Derrick J. Rossi | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Erik J. Sontheimer | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Luciano Marraffini | Founder and Member of Scientific Advisor Board | 1.38M | N/A |
| Jason Fredette | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Rachel E. Haurwitz | Co-Founder | 0 | 1986 |
| Eliana Clark | Executive VP & Chief Technical Officer | 0 | 1958 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.